Ashley D Williams

Address:

4500 Pear Rdg Dr APT 631, Dallas, TX 75287

VIN:

3FAHP0HA8AR390364

Make:

FORD

Model:

FUSION

Year:

2010

US Patent:

7492364, Feb 17, 2009

Filed:

Jul 23, 2003

Appl. No.:

10/626494

Inventors:

Venkat Devarajan - Arlington TX, US
Raj Ganesan Iyer - Sterling Heights MI, US
Sharon Barber - Arlington TX, US
Niranjan Dharmarajan - Bellevue WA, US
Savitha Ganapathi - Arlington TX, US
Navaneetha Krishnan Subramanian - Arlington TX, US
Vijayajeevan Jothi Nana - Arlington TX, US
Saurabh Maitra - Arlington TX, US
Ashley Scott Williams - Fort Worth TX, US

Assignee:

Imagecom, Inc. - Arlington TX

International Classification:

G06T 17/00
G06T 15/00

US Classification:

345420, 345419

Abstract:

The present invention discloses a method for building, defining, and storing features in an application neutral format comprising building a feature based on a feature class, wherein the feature class comprises feature geometry, feature constraints, and feature dimensions, defining the built feature as a geometric representation of an individual feature type, and storing the representation in a binary file format.

US Patent:

20220389462, Dec 8, 2022

Filed:

Apr 26, 2022

Appl. No.:

17/660663

Inventors:

- Fort Collins CA, US
Ashley B. Williams - Austin TX, US
Darcy Mora - Fort Collins CO, US
Melissa Vivian - Fort Collins CO, US
Connie Brewster - Bellvue CO, US

Assignee:

SiVEC Biotechnologies LLC - Fort Collins CO

International Classification:

C12N 15/90
C12N 15/11
C12N 15/70
C12N 9/22
C07K 14/195

Abstract:

A transkingdom platform for the delivery of therapeutics to target cells. The system maintains the export and uptake functions of Inv while modifying its targeting away from 1 integrin to other proteins expressed on the surface of target eukaryotic cells (i.e., a cell surface protein) or chemical moieties (i.e., a cell surface chemical moiety) expressed on the surface of a target eukaryotic cell by replacing D4 and D5 of Inv with a binding domain from a heterologous protein via genetic engineering. These heterologous proteins could be derived from bacterial, fungal, animal, or viral genomes. This engineering would result in the construction of a chimeric Inv protein in which D1-D3 (i.e., the non-binding domains) are fused in frame to an alternative binding domain derived from a heterologous protein. The alternative binding domain would interact with a different cell surface protein or chemical moiety, which can in some instances be referred to as a receptor, on the surface on the surface of a eukaryotic cell, thereby allowing specific targeting to cells independent of Inv's intrinsic 1 integrin binding.

US Patent:

20210222178, Jul 22, 2021

Filed:

Jan 11, 2021

Appl. No.:

17/146391

Inventors:

- Fort Collins CO, US
Ashley B. Williams - Austin TX, US
Darcy Mora - Fort Collins CO, US
Madeline Cox - Laporte CO, US

Assignee:

SiVEC Biotechnologies LLC - Fort Collins CO

International Classification:

C12N 15/70
A61K 35/74

Abstract:

A bacterial system for the generation and delivery of eukaryote-translatable mRNA to eukaryotic cells. The system uses invasive, non-pathogenic bacteria to generate and deliver functional mRNA cargo to eukaryotic cells. Additionally, the system uses bacteria to generate functional mRNA that can be extracted from the bacterial cell for downstream applications. The bacteria contain at least one prokaryotic expression cassette encoding the mRNA; the mRNA contains a bacterially transcribed poly-A sequence, and a 5′ cap or pseudo-cap element, e.g., an internal ribosome entry site (IRES) element, that will mediate translation in the eukaryotic host cell. Examples of therapeutic mRNA function include, but are not limited to, providing genetic material encoding antibodies, vaccine antigens, and defective genes in the host.